"Ondansetron" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Descriptor ID |
D017294
|
| MeSH Number(s) |
D03.383.129.308.690 D03.633.100.473.144.500 D03.633.300.148.500
|
| Concept/Terms |
Ondansetron Hydrochloride- Ondansetron Hydrochloride
- Hydrochloride, Ondansetron
- Ondansetron Monohydrochloride
- Monohydrochloride, Ondansetron
- Ondansetron Monohydrochloride Dihydrate
- Dihydrate, Ondansetron Monohydrochloride
- Monohydrochloride Dihydrate, Ondansetron
|
Below are MeSH descriptors whose meaning is more general than "Ondansetron".
Below are MeSH descriptors whose meaning is more specific than "Ondansetron".
This graph shows the total number of publications written about "Ondansetron" by people in this website by year, and whether "Ondansetron" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 1 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ondansetron" by people in Profiles.
-
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
-
An exploratory study of the relationship between postoperative nausea and vomiting and postdischarge nausea and vomiting in children undergoing ambulatory surgery. Paediatr Anaesth. 2019 04; 29(4):353-360.
-
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology. 2019 01; 44(2):390-398.
-
Nausea and vomiting: Therapeutic orphans of pediatric oncology. Pediatr Blood Cancer. 2017 10; 64(10).
-
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597.
-
Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. JAMA Pediatr. 2014 Apr; 168(4):321-9.
-
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Support Care Cancer. 2013 Oct; 21(10):2845-51.
-
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer. 2013 Apr 01; 119(7):1428-36.
-
Deciphering a neuronal circuit that mediates appetite. Nature. 2012 Mar 14; 483(7391):594-7.
-
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66.